



Divi's Laboratories Limited

February 11, 2026

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on February 11, 2026

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our intimation dated January 30, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on February 11, 2026, inter-alia, have approved the unaudited financial results for the quarter and nine months ended December 31, 2025. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of standalone unaudited financial results for the quarter and nine months ended December 31, 2025, along with Limited Review Report of the Statutory Auditors thereon.
2. Statement of consolidated unaudited financial results for quarter and nine months ended December 31, 2025, along with Limited Review Report of the Statutory Auditors thereon.
3. Press Release on the financial results of the Company.

The Board meeting commenced at 11:00 Hrs and concluded at 12.25 Hrs.

This is for your information and records.

Thanking you,
Yours faithfully,
For Divi's Laboratories Limited

M. Satish Choudhury
Company Secretary & Compliance Officer

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2025

(Rs. in Crores)

S. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income:						
	Revenue from operations	2578	2660	2297	7595	6662	9198
	Other income	87	146	82	352	265	352
	Total income	2665	2806	2379	7947	6927	9550
2	Expenses						
	a) Cost of materials consumed	1191	907	1015	3087	2850	3760
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(246)	144	(87)	(174)	(142)	(83)
	d) Employee benefits expense	356	344	288	1030	869	1210
	e) Depreciation and amortisation expense	116	113	99	341	294	401
	f) Finance costs	6	8	-*	17	1	1
	g) Other expenses	370	370	334	1107	987	1332
	Total expenses	1793	1886	1649	5408	4859	6621
3	Profit before exceptional items and tax (1-2)	872	920	730	2539	2068	2929
4	Exceptional items						
	Impact of new Labour Codes (Refer note 4)	74	-	-	74	-	-
5	Profit before tax (3-4)	798	920	730	2465	2068	2929
6	Tax expense						
	a) Current tax	208	220	172	619	568	793
	b) Deferred tax	(8)	4	(36)	(5)	(42)	(73)
	Total tax expense	200	224	136	614	526	720
7	Profit for the period/year (5-6)	598	696	594	1851	1542	2209
8	Other comprehensive income:						
	Items that will not be reclassified to Profit or Loss:						
	(i) Gain/(Loss) on Remeasurement of post-employment benefit obligation	17	-*	(1)	16	(2)	(3)
	ii) Income tax relating to the above	(4)	-*	1	(4)	1	1
	Total other comprehensive income (i+ii)	13	-*	-*	12	(1)	(2)
9	Total comprehensive income for the period/year (7+8)	611	696	594	1863	1541	2207
10	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	53	53	53	53	53	53
11	Other equity excluding revaluation reserve						14842
12	Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized)						
	a) Basic (Rs.)	22.56	26.24	22.39	69.75	58.08	83.20
	b) Diluted (Rs.)	22.56	26.24	22.39	69.75	58.08	83.20

#Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the company.



Kai Di



DIVI'S LABORATORIES LIMITED

NOTES:

1. The above Statement of Standalone Unaudited Financial Results ('Standalone Statement') for the quarter and nine months ended 31st December, 2025 is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Standalone Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11th February, 2026. The statutory auditors have carried out a limited review of this Standalone Statement and issued an unmodified report thereon.
2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.
3. The Company does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
4. On November 21, 2025, the Government of India notified the four labour codes viz., the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') consolidating twenty-nine existing labour laws. The Ministry of Labour and Employment published draft central rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the impact based on the best available information and recognised the incremental impact of employee benefits expense of Rs.74 crores. The said incremental impact primarily arises due to change in the definition of wages and the same has been accounted in accordance with the applicable accounting standards. Considering its non-recurring nature and amount involved, such incremental impact is presented under "Exceptional items" in the Standalone Statement. The Company will continue to monitor the finalisation of Central and State Rules, clarifications from the government on other aspects of the Labour Codes and will provide appropriate impact, if any, on measurement of liability for employee benefits when available.
5. Forex gain included in Other Income for the respective periods is as given below.

(Rs. in Crores)

	Quarter ended			Nine Months ended		Year ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
Forex gain	18	64	11	121	37	48

Place: Hyderabad
Date: 11th February, 2026

For Divi's Laboratories Limited

Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended December 31, 2025 and the year to date results for the period April 01, 2025 to December 31, 2025, which are included in the accompanying Statement of Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2025 (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review.
2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan
Partner
Membership Number: 90196
UDIN: 26090196PNXPUH6403

Place: Hyderabad
Date : February 11, 2026

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP Identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025**

(Rs. in Crores)

S. No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income:						
	Revenue from operations	2604	2715	2319	7729	6775	9360
	Other income	88	145	82	352	266	352
	Total income	2692	2860	2401	8081	7041	9712
2	Expenses						
	a) Cost of materials consumed	1217	937	1021	3164	2890	3821
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(272)	136	(99)	(190)	(146)	(96)
	d) Employee benefits expense	367	354	297	1061	893	1243
	e) Depreciation and amortisation expense	118	113	99	343	295	402
	f) Finance costs	6	8	-*	17	1	2
	g) Other expenses	402	400	357	1187	1056	1424
	Total expenses	1838	1948	1675	5582	4989	6796
3	Profit before exceptional items and tax (1-2)	854	912	726	2499	2052	2916
4	Exceptional items						
	Impact of new Labour Codes (Refer note 5)	74	-	-	74	-	-
5	Profit before tax (3-4)	780	912	726	2425	2052	2916
6	Tax expense						
	a) Current tax	208	220	174	619	571	799
	b) Deferred tax	(11)	3	(37)	(11)	(48)	(74)
	Total tax expense	197	223	137	608	523	725
7	Profit for the period/year (5-6)	583	689	589	1817	1529	2191
8	Profit for the period/year attributable to:						
	Shareholders of the Company	583	689	589	1817	1529	2191
	Non-Controlling Interest	-	-	-	-	-	-
9	Other Comprehensive Income:						
	a) Items that will not be reclassified to profit or loss:						
	i) Gain/(loss) on Remeasurement of post-employment benefit obligations	17	-*	(1)	16	(2)	(3)
	ii) Income tax relating to the above	(4)	-*	1	(4)	1	1
	b) Items that will be reclassified to profit or loss:						
	i) Gain on exchange differences in translating the financial statements of foreign operations	4	5	1	13	5	6
	ii) Income tax relating to the above	(1)	(2)	-	(3)	(1)	(1)
	Total other comprehensive income (a+b)	16	3	1	22	3	3
10	Total other comprehensive income for the period/ year attributable to:						
	Shareholders of the Company	16	3	1	22	3	3
	Non-Controlling Interest	-	-	-	-	-	-
11	Total comprehensive income for the period/year (7+9)	599	692	590	1839	1532	2194
12	Total comprehensive income for the period/ year attributable to:						
	Shareholders of the Company	599	692	590	1839	1532	2194
	Non-Controlling Interest	-	-	-	-	-	-
13	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	53	53	53	53	53	53
14	Other equity excluding revaluation reserve						14916
15	Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized)						
	a) Basic (Rs.)	21.98	25.97	22.20	68.44	57.60	82.53
	b) Diluted (Rs.)	21.98	25.97	22.20	68.44	57.60	82.53

#Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the group.

Kai Di



DIVI'S LABORATORIES LIMITED

NOTES:

1. The above Statement of Consolidated Unaudited Financial Results ('Consolidated Statement') for the quarter and nine months ended 31st December, 2025 is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Consolidated Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11th February, 2026. The statutory auditors have carried out a limited review of this Consolidated Statement and issued an unmodified report thereon.
2. The Consolidated Unaudited Financial Results include the financial results of Divi's Laboratories Limited ('Parent Company') and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (together referred as the "Group")
3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108.
4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
5. On November 21, 2025, the Government of India notified the four labour codes viz., the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') consolidating twenty-nine existing labour laws. The Ministry of Labour and Employment published draft central rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Parent Company has assessed the impact based on the best available information and recognised the incremental impact of employee benefits expense of Rs.74 crores. The said incremental impact primarily arises due to change in the definition of wages and the same has been accounted in accordance with the applicable accounting standards. Considering its non-recurring nature and amount involved, such incremental impact is presented under "Exceptional items" in the Consolidated Statement. The Parent Company will continue to monitor the finalisation of Central and State Rules, clarifications from the government on other aspects of the Labour Codes and will provide appropriate impact, if any, on measurement of liability for employee benefits when available.
6. Forex gain included in Other Income for the respective periods is as given below.

(Rs. in Crores)

	Quarter ended			Nine Months ended		Year ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
Forex gain	19	63	10	121	38	48

Place: Hyderabad
Date: 11th February, 2026

For Divi's Laboratories Limited



Dr. Kiran S Divi
Whole-time Director and
Chief Executive Officer



Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent") and its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group"), (refer Note 2 on the Consolidated Statement) for the quarter ended December 31, 2025 and the year to date results for the period April 01, 2025 to December 31, 2025 which are included in the accompanying Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025 (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been initialled by us for identification purposes.
 2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.
 3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Consolidated Statement includes the results of the following entities:
 - a) Divis Laboratories (USA) Inc.
 - b) Divi's Laboratories Europe AG



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



N.K. Varadarajan
Partner
Membership Number: 90196
UDIN: 26090196RSTQRD6674

Place: Hyderabad
Date : February 11, 2026



DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

PRESS RELEASE DATED 11th FEBRUARY 2026

Divi's Laboratories earns a Consolidated Total Income of ₹2692 crores for Q3 of FY26

Consolidated Financial Results

For the quarter ended 31st December 2025

Divi's Laboratories has earned a consolidated total income ₹2692crores for the quarter ended 31st December 2025 as against a consolidated total income of ₹2401 crores for the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter amounted to ₹780 crores (after the impact of labour codes of ₹74 crores) as against a PBT of ₹726 crores for the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter amounted to ₹583 crores as against a PAT of ₹589 crores for the corresponding quarter of the previous year. For the current quarter, we have forex gain of ₹19 crores as against a gain of ₹10 crores during the corresponding quarter of the previous year.

For the Nine months period ended 31st December 2025

For the nine months period ended 31st December 2025, the Company earned a consolidated total income of ₹8081 crores as against a consolidated total income of ₹7041 crores during the corresponding nine months period of the previous year. PBT for the current nine months period amounted to ₹2425 crores (after the impact of labour codes of ₹74 crores), as against ₹2052 crores for the corresponding nine months period of the previous year. PAT for the current period amounted to ₹1817 crores as against ₹1529 crores for the corresponding period of the previous year. For the current period we had a forex gain of ₹121 crores against a gain of ₹38 crores for the corresponding period of the previous year.

Standalone Financial Results

On a standalone basis, the Company's earnings are as given below:

₹ in crores

Particulars	For the Quarter ended		For the nine months period ended	
	31-12-2025	31-12-2024	31-12-2025	31-12-2024
Total Income	2665	2379	7947	6927
PBT before exceptional item	872	730	2539	2068
Exceptional item*	74	--	74	--
PBT	798	730	2465	2068
Tax Expense	200	136	614	526
PAT	598	594	1851	1542

*Statutory impact of labour codes

Forex gain for the period, on standalone basis, is as given below:

₹ in crores

Particulars	For the Quarter ended		For the nine months period ended	
	31-12-2025	31-12-2024	31-12-2025	31-12-2024
Forex gain	18	11	121	37



Kai Di